The structure of myeloid cell-specific TNF inhibitors affects their biological properties

FEBS Lett. 2020 Nov;594(21):3542-3550. doi: 10.1002/1873-3468.13913. Epub 2020 Sep 4.

Abstract

Spatial organization and conformational changes of antibodies may significantly affect their biological functions. We assessed the effect of mutual organization of the two VH H domains within bispecific antibodies recognizing human TNF and the surface molecules of murine myeloid cells (F4/80 or CD11b) on TNF retention and inhibition. TNF-neutralizing properties in vitro and in vivo of MYSTI-2 and MYSTI-3 antibodies were compared with new variants with interchanged VH H domains and different linker sequences. The most effective structure of MYSTI-2 and MYSTI-3 proteins required the Ser/Gly-containing 'superflexible' linker. The orientation of the modules was crucial for the activity of the proteins, but not for MYSTI-3 with the Pro/Gln-containing 'semi-rigid' linker. Our results may contribute toward the development of more effective drug prototypes.

Keywords: VHH; anti-TNF therapy; bispecific antibodies; linkers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Bispecific / pharmacology
  • Chemical and Drug Induced Liver Injury
  • Galactosamine
  • Humans
  • Lipopolysaccharides
  • Macrophages / drug effects
  • Mice
  • Myeloid Cells / drug effects*
  • Survival Rate
  • Tumor Necrosis Factor Inhibitors / pharmacology*
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Antibodies, Bispecific
  • Lipopolysaccharides
  • Tumor Necrosis Factor Inhibitors
  • Tumor Necrosis Factor-alpha
  • Galactosamine